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responsibility of InAbstract For many years, drug delivery to the inner ear has been a challenge to physicians in the
treatment of inner ear disorders. In the past decade, the ﬁeld of inner ear drug delivery has emerged
with the development of new biomaterials and drug delivery technologies to improve the
effectiveness of inner ear drug therapy. This paper reviews a number of inner ear drug delivery
strategies including systemic, intratympanic, and intracochlear delivery. A focus of this review is the
recent advances in intratympanic delivery of medications; approaches utilizing novel biomaterials
as well as other recent developments are also discussed. Biotechnology-based approaches, such as
gene and stem cell therapy methods are also reviewed. Among the various strategies, local drug
delivery approaches including intratympanic and intracochlear drug delivery methods that limit
systemic exposure are particularly promising. These inner ear drug delivery systems provide a new
opportunity to improve the treatment of inner ear disorders.
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Inner ear drug delivery has been a challenge to physicians in the
treatment of inner ear disorders. In the past decade, new
biomaterials and drug delivery technologies have been developed
for inner ear delivery. Swan et al.1 published a comprehensive
review on inner ear drug delivery in 2008. In the same year,
Borkholder2 reviewed the status of inner ear delivery via the
intratympanic and intracochlear routes. Since then, the ﬁeld of
inner ear drug delivery has gained a lot of interest and advanced
rapidly. Several other review articles on inner ear drug delivery
have been published in the past ﬁve years. Table 1 provides a list
of these papers. These reviews focus either on a particular drug
delivery strategy, a speciﬁc type of material or disease, or a
combination of these topics in the ﬁeld. The goal of the present
review is to provide an updated general overview of inner ear drug
delivery. We ﬁrst review the administrative routes for inner ear
drug delivery and then compare their advantages and disadvan-
tages, discussing their potential as a result of recent advances in
biomaterials, delivery technologies, and biotechnology methods.
Recent developments in inner drug delivery strategies such as
intratympanic and biotechnology-based approaches are high-
lighted. The strategies of inner ear drug delivery reviewed in this
paper are listed in Table 2.2. Anatomy relevant to inner ear drug delivery
To understand the challenges of drug delivery to the inner ear,
the anatomy relevant to inner ear drug delivery is ﬁrst
discussed. The inner ear in humans consists of the bony
labyrinth, a system of passages comprising two main parts:
(a) the cochlea dedicated to hearing and (b) vestibular systemTable 1 Review articles related to inner ear drug delivery.
Review subject of focus
Inner ear drug delivery applications and methods
Transtympanic and intracochlear drug delivery
Pharmacokinetics of inner ear
Clinical opinion on inner ear drug delivery and current status
of inner ear disease treatment
Cochlear implant
Nanoparticles
Intracochlear drug delivery
Biodegradable materials
Protective agents against sensorineural hearing loss
Nanoparticles
Sensorineural hearing loss, animal model for evaluation
New technologies on drug delivery device
Table 2 Comparison of various strategies in inner ear drug deliv
Strategy Efﬁciency Safety
Systemic strategies Low Low safety, s
Intratympanic
strategies
Moderate, produce variable
outcome
High safety,
physician’s
Intracochlear
strategies
High Limited safet
complicatiodedicated to balance. Blood labyrinth barrier (BLB) and
round window membrane (RWM) are described below
because these parts constitute the barriers of drug delivery
to the inner ear.
2.1. Blood labyrinth barrier
BLB is a major barrier separating the inner ear from systemic
circulation with tight junctions, made up of capillary endothelial
cells that line blood vessels located in the stria vascularis13–15. It
plays an important role in maintaining the microhomeostasis of
the inner ear ﬂuid and protecting the inner ear integrity similar to
the function of the blood brain barrier (BBB) to the brain16. BLB
functions not only as a physical barrier but also as a biochemical
barrier with efﬂux pump systems, including P-gp (P-glycopro-
tein) and MRP-1 (multidrug resistance-related protein-1). These
efﬂux systems further protect the inner ear17. Thus, the BLB is
often considered as the rate-limiting barrier in the permea-
tion of therapeutic agents from systemic circulation to the inner
ear.
The current knowledge on the processes of drug transport
through BLB in the literature is limited. The BLB consisting of
tight junctions generally permits only the permeation of small
lipid-soluble molecules1. Although the actual mechanism of
tight junction opening of BLB is not clear, a number of factors
were found to lead to tight junction opening of the BLB,
including the presence of ototoxic drugs18, noises19 and
inﬂammation20. It has been reported that aminoglycosides
given systemically in combination with diuretics such as
furosemide or ethacrynic acid result in hearing loss and inner
ear damage faster than that of aminoglycosides alone21,22.
This suggests that the diuretics can enhance drug penetration
across the BLB. Particularly, osmotic agents were suggested toYear Author
2008 Swan et al.1
2008 Borkholder2
2009 Salt and Plontke3
2010 McCall et al.4
2010 Staecker et al.5
2010 Chen et al.6
2011 Borenstein7
2011 Nakagawa and Ito8
2011 Mukherjea et al.9
2011 Pyykko et al.10
2012 Rivera et al.11
2012 Pararas et al.12
ery.
ide effects caused by high systemic doses over time
minimally invasive procedure that can be performed in a
ofﬁce
y, precise surgery is needed and potential of serious
ns
Hongzhuo Liu et al.88induce endothelial cell ‘‘shrinkage’’ and thereby lead to the
opening of BLB tight junction23. Glycerol, an osmotic agent,
was shown to increase the concentrations of drugs such as
vasodilators and steroids in the lymph of the inner ear after
systemic administration. In addition to chemicals, hearing
disorders such as autoimmune inner ear disease (AIED),
Meniere’s disease, meningitis-associated labyrinthitis, and
genetic diseases can also affect the BLB.
2.2. Round window membrane
The round window membrane (RMW) is a soft tissue barrier
separating the middle ear from the inner ear. It is the main
passage for drug delivery from the middle ear cavity to the
inner ear. The RWM is made up of an outer epithelial layer
facing the middle ear cavity, middle connection layer, and
inner cellular layer facing the scala tympani (ST) peri-
lymph24–26. The variable RWM thickness and conditions of
the membrane across the patient population is believed to be a
factor leading to patient-to-patient variability in intratympa-
nic inner ear drug delivery. Additionally, the pseudomem-
brane of the RWM (plugs of connective or adipose tissue) also
accounts for this variability27.
The RWM acts like a semipermeable membrane. It is
permeable primarily to low molecular weight molecules such
as aminoglycoside antibiotics and corticosteroids. Large
molecules, such as horseradish peroxidase (MW 45,000), can
also diffuse through RWM under normal physiological con-
ditions28. While larger molecules like albumin (MW 70,000)
cannot diffuse across the RWM easily under normal condi-
tions, such large molecules have been shown to penetrate the
RWM into the inner ear during the early phase of inﬂamma-
tion29. Besides the molecular weights of the drugs and disease
states of the ear, other factors including the integrity of the
RWM and drug lipophilicities and charges also affect the rates
at which the molecules diffuse across the RWM14. In addition,
the permeability of RWM is affected by local treatments with
anesthetics30, endotoxins and exotoxins31, histamine32, osmo-
tic disturbances, and benzyl alcohol (a commonly used
preservative)33.3. Administration routes for inner ear drug delivery
3.1. Systemic route
Generally, drugs are delivered to the inner ear via the systemic
route, but only a few drugs can reach the target site of action at
therapeutic concentrations in the inner ear because of the presence
of BLB. In order to achieve therapeutic levels of drugs in the inner
ear, high systemic doses are required, which are often associated
with undesirable side effects1,4,34. Such systemic toxicities and side
effects can range from minor nuisances to potentially life-
threatening situations4. Despite these adverse effects, systemic
delivery through oral, intravenous, and intramuscular routes is
still considered as the most convenient method of drug adminis-
tration to the inner ear and is currently accepted as the ﬁrst line
approach in the treatment of inner ear disorders. Systemic
corticosteroids, for example, are used in the management of
sudden sensorineural hearing loss (SSNHL) and AIED35,36 in
spite of potential side effects such as hypertension, irritability,
cushingoid appearance and organ damage associated with long-term systemic steroid therapy37. Several studies have demonstrated
that systemic administration of lidocaine can relieve tinnitus, but
the treatment of tinnus by lidocaine systemically involves the risks
of arrhythmia and central nervous system excitation or depres-
sion38. Another treatment of inner ear disorders via the systemic
route is the use of streptomycin and gentamicin, which are
ototoxic, in severe bilateral Meniere’s diseases39,40. The lack of
selective pharmacological effects of systemic streptomycin and
gentamicin on hearing and balance has led to hearing loss in
clinical interventions of Meniere’s diseases41. Other drugs that
have been delivered systemically to the inner ear in conjunction
with gentamicin are glutathione42, salicylate43, alpha-toco-
pherol44,45, trimetazine46 and ﬂavonoids47 for their protective
effects on hearing loss or histological damages in gentamicin
treatment.
Encouraged by the successful application of nanoparticles
targeted to the brain, researchers have investigated the potentials
of nanoparticles in inner ear drug delivery by systemic adminis-
tration. Tamura et al.48 found that the systemic application of
poly lactic/glycolic acid (PLGA) nanoparticles of rhodamine
provided targeted delivery of rhodamine to the liver but not the
cochlea. Horie et al.49 discussed the limited capability of
nanoparticles for sustained and/or targeted delivery of drugs to
cochlea after systemic application, which might be related to rapid
clearance of the nanoparticles from circulation by the mono-
nuclear phagocyte system (MPS) in the liver and spleen. They
subsequently examined the efﬁcacy of stealth nanoparticles encap-
sulating betamethasone phosphate (BP) for the treatment of noise-
induced sensorineural hearing loss in mice. The results in their
study demonstrated that stealth-nano-BP could deliver higher level
of BP to the cochlea than free BP without the nanoparticles
(Fig. 1). In addition to the pharmacokinetic data, immunohisto-
chemistry for the glucocorticoid receptor showed remarkable
enhancement of glucocorticoid receptor nuclear translocation in
outer hair cells of cochlea treated with the stealth-nano-BP. This
treatment provided functional and histological protection of the
cochlea from the trauma of noise as compared to those with free
BP. However, this method was still accompanied by a high drug
concentration in the blood plasma as well as in organs such as the
liver, which might lead to adverse systemic effects. With the
problems in systemic drug delivery, there is a need to design a
safer and more effective drug delivery system for the treatment of
inner ear disorders.3.2. Intratympanic route
In the last two decades, the topic of treating inner-ear disorders
by local drug delivery has attracted considerable interest.
Intratympanic delivery to the inner ear was performed via the
injection or perfusion of the drug to the middle ear with the aim
of drug diffusion through the RWM into the inner ear. This
route of drug delivery was introduced more than half a century
ago for the treatment of Meniere’s disease with local anes-
thetics50 and antibiotics51,52 and has been widely used in clinics
since 1990s. This approach possesses several advantages over
systemic drug delivery as this local drug delivery method can
bypass the BLB, and therefore result in higher drug concentra-
tions in the inner ear ﬂuids and avoid undesired systemic
exposure1,4,34. A number of clinical studies have been published
on intratympanic injections of corticosteroids for Meniere’s
diseases53–55 and SSNHL56,57. Obstacles of intratympanic drug
Figure 1 Betamethasone phosphate (BP) concentrations in the
cochlea after systemic applications of stealth-nano-BP or free BP.
The concentrations of BP in the cochlea after stealth-nano-BP
application (diamonds) were signiﬁcantly higher than those after
free BP application (squares). The level of BP in the cochlea after
stealth-nano-BP application was also maintained for a longer
period of time. Data were obtained from Horie et al.49
Current strategies for drug delivery to the inner ear 89delivery include the anatomic barriers to drug absorption from
the middle ear to the inner ear such as the RWM, loss of drug in
the middle ear through the Eustachian tube, and highly variable
or unknown pharmacokinetic proﬁles of medications delivered
via this route27,34,58. The percentage of drugs entering the inner
ear following intratympanic injections can be relatively low. For
example, one study showed that gentamicin reaching the basal
turn was in the order of 2.5% of the applied drug after
intratympanic injection59. Drug clearance in the cochlea is also
a major factor that leads to a base–apex concentration gradient.
Due to this concentration gradient, it may be difﬁcult to treat
hearing disorders in the middle and lower frequency ranges
(disorders in the apex area) by the intratympanic drug delivery
approaches. In addition, it is difﬁcult to predict the amounts of
drugs delivered to the cells in different turns of the cochlea even
though computational simulations have been used to study the
base–apex concentration gradient60–62.
Effective drug delivery to the inner ear via the intratympa-
nic route also relies on the contact time of the drug solution
(or drug delivery system) with the RWM. Unfortunately, large
portions of the administered drugs are usually eliminated
through the Eustachian tube following intratympanic drug
delivery. There have been efforts to overcome this limitation
through the development of devices and sustained-release drug
delivery systems. This is the focus of the present review paper
and is discussed in Section 4.
3.3. Intracochlear route
Like intratympanic delivery, the intracochlear delivery approach
provides an alternative to systemic drug delivery to the inner ear.
Direct intracochlear drug delivery can bypass the middle ear and
allow drugs to get to their intended sites directly. Intracochlear
delivery can substantially increase drug bioavailability in the inner
ear and has the highest efﬁciency among the inner ear delivery
methods discussed in this review. Numerous intracochlear delivery
technologies are being developed to improve the efﬁciency of drug
delivery to the inner ear. They include direct injections, cochlear
implants, osmotic mini-pumps, as well as reciprocating perfusionsystems. Direct injection is the injection of drug solution directly
into the cochlea through the RWM with a microsyringe and a
narrow-gauge needle. This provides accurate drug delivery for
acute drug application to the base of the cochlea. Cochlear
implant is a device inserted into the ST in the treatment of inner
ear disorders. The basic mechanism behind this treatment is to
directly simulate SGNs with electrical pulses through an electrode,
overcoming the loss of hair cells in the cochlea5. However, it was
recognized that the process of electrode insertion deep into the
cochlea could destroy the remaining acoustic hearing due to
various complications associated with implantation5. Thus, this
method is most used for the treatment of severe to profound
SSNHL. A recent development with cochlear implant was the
concurrent use of drugs with implant to reduce trauma to the
inner ear or to prevent further degeneration of hearing after
implantation63,64. Osmotic mini-pumps are used to directly deliver
drugs into ST via cannula, and reciprocating perfusion systems are
similar to osmotic mini-pumps with the main difference that there
is no accompanying net volume change of ﬂuid in the reciprocat-
ing perfusion systems65. Recently, Sewell et al.66 developed a
implantable reciprocating inner ear drug delivery system which
could provide time-sequence release of multiple agents for
therapeutic applications. This approach is suggested to be best
suited for controlled automatically complex dosing of numerous
compounds. Although intracochlear strategies are more efﬁcient
than intratympanic delivery, they carry signiﬁcant risks7. Based on
observations in surgical procedures that involve perforation of the
inner ear such as stapedectomy or the cochlear implantation on
patients, it is well known that perforation and surgical manipula-
tion of the ear leads to a signiﬁcant risk of deafness67,68. Currently,
a safe and robust technique for intracochlear delivery of drugs is
not available.3 These technologies have been summarized in a
recent review paper7 and will not be discussed here in detail.4. Intratympanic approaches to inner ear drug delivery
4.1. Cannula-based delivery systems
Several cannula-based delivery systems are available commer-
cially for sustained delivery of drugs to the middle ear. These
devices include Silverstein Microwick and Round Window
Microcatheter. Potential problems and adverse effects of these
devices include the persistent perforation of the tympanic
membrane, risk of infection in the middle ear or external ear,
and tissue growth in the middle ear either in the form of
ﬁbrosis or epithelial ingrowth leading to cholesteatoma69,70.4.1.1. Silverstein Microwick
The Microwick (Micromedics, Inc., Eagan, MN) is a single-
wick device placed in the round window niche through a
tympanostomy opening71. The distal end of wick is in the
external auditory canal, where the patients can instill medica-
tions several times a day for several weeks. Recent studies
have demonstrated the reliability and consistency of gentami-
cin and methylprednisolone delivery by this device72. Long-
term followed-up of 69 Meniere’s disease patients treated with
gentamicin three times per day using this system has demon-
strated vertigo control in 53 patients (76.8%)73.
Hongzhuo Liu et al.904.1.2. Round Window Microcatheter
The Round Window Microcatheter is a double lumen-
sustained microcatheter inserted into the round window niche
designed to deliver drugs to the inner ear.74 The catheter can
be inserted into the middle ear and connected to a pump. This
system has the advantage of delivering drugs to the middle ear
continuously for several days to a few weeks. For example, by
using a minipump attached to a microcatheter, gentamicin
could be delivered for 10 days74. In another report, Panomat
pump provided continuous delivery of glucocorticoid for a
period of up to 4 weeks75. The microcatheter system has also
been used for intratympanic infusion of steroids in patients
with sensorineural hearing loss who have failed in the treat-
ment with intravenous steroids and vasodilators76. When the
microcatheter was used to deliver gentamicin to the RWM to
treat the symptoms in Meniere’s diseases, 60–83% patients got
relief of their tinnitus and 89–100% patients recovered from
vertigo symptoms, which is a signiﬁcant improvement over the
cure rates reported with conventional intratympanic adminis-
tration of gentamicin77.
4.2. Sustained-release systems
Sustained-release drug delivery systems can increase the
residence time of a drug in the middle ear and provide
controlled drug delivery to the inner ear. A number of systems
including hydrogels and nanoparticles have been studied for
this application (Table 3). These systems generally sustain
drug delivery by the mechanisms of slow degradation of the
material, slow drug diffusion, or a combination of both.
4.2.1. Hydrogels
Gelfoams is a biodegradable gelatin polymer that was ﬁrst
introduced in middle ear surgery and recently used as a drug
delivery system for the inner ear. A recent study has demon-
strated improved outcome of Meniere’s disease treatment by
the placement of Gelfoams soaked in gentamicin on the
RWM, which eliminated vertigo and tinnitus in 75% and 48%
of the patients, respectively78. In another study, Havenith
et al.79 applied Gelfoams inﬁltrated with brain-derived
neurotrophic factor (BDNF) onto the RWM of deafened
guinea pigs and evaluated the effect of this treatment by
structural and functional measures. In the 2 weeks of Gel-
foams BDNF treatment, survival of spiral ganglion neurons
(SGNs) in the inner ear was observed in the low turn of the
cochlea, but no signiﬁcant improvement was observed in the
apical turn of the cochlea, probably due to the small amount
of drug reaching the apical turn. This suggests that local
delivery of BDNF using Gelfoams can protect the SGNs in
parts of the cochlea. However, Richardson et al.24 did not
achieve SGN survival after 4 weeks of treatment using
Gelfoams loaded with neurotrophin-3 (NT-3) on the RWM
of deafened guinea pigs.
Several hydrogel systems for inner ear drug delivery employ
hyaluronic-based chemistry. Hyaluronic acid (HA) is an anionic,
nonsulfated glycosaminoglycan polysaccharide that is present in
human body. It has been used as material in otology due to its
well-known safety proﬁle80. A commercial hydrogel Sepra-
packTM (hyaluronic acid–carboxymethyl cellulose polymer, Gen-
zyme Corporation) has been examined for the delivery of
dexamethasone to the inner ear. The use of dexamethasone withSeprapackTM via the intratympanic route on the RWM was
found to reduce both low and high frequency hearing loss
associated with trauma of cochlear implantation81. Similarly, n-
acetyl cysteine with SeprapackTM was shown to be effective to
protect the residual hearing after implant surgery in the high
frequency hearing region near the point of implantation82. James
et al.83 investigated the concentration of dexamethasone in the
cochlea after intratympanic delivery with SeprapackTM and
found signiﬁcantly higher and sustained concentration of the
drug in the cochlea than that by the drug alone without
SeprapackTM. These results were similar to those reported by
Borden et al.84 who utilized the thiol-modiﬁed HA gelatin
hydrogel as a drug delivery system. Saber et al.80 suggested that
hyaluronic gel had no toxic effect on the hair cells but found that
the gel temporary increased the thickness of RWM. The
membrane returned to normal after 4 weeks, indicating that this
material caused no permanent structural damage to the RWM.
Several other hydrogels were also studied for inner ear drug
delivery through the intratympanic route. For example, a
hydrogel of glutaraldehyde cross-linked with porcine type-I
collagen was examined for the sustained delivery of BDNF to
the inner ear. This treatment was shown to provide a
protective effect manifested by stable auditory brainstem
response (ABR) thresholds and preservation of spiral ganglion
neuron densities in animals85. In another study, gelatin
hydrogel loaded with hepatocyte growth factor was found to
provide sustained drug delivery to the inner ear in guinea
pigs86. Saber et al.87 compared the feasibility of three structu-
rally different chitosans as bioadhesives to deliver drugs to the
inner ear through the RWM. All these bioadhesive gel
formulations provided effective neomycin delivery to the
cochlea over 7 days. The chitosans were free from any
detectable toxicity on the cochlear tissue. Among the chitosans
studied, glycosylated chitosan was considered as a promising
biomaterial for inner ear therapy due to its safety and
efﬁciency.
Another type of hydrogels for sustained drug delivery to the
inner ear is temperature sensitive polymers (e.g., sol–gel polymers).
These polymers provide the advantage of solution to gel transition
near body temperature. Particularly, the sol–gel polymer with a
drug can be delivered as a solution through intratympanic
injection using a narrow-gauge needle at room temperature, and
the polymer solution then becomes a gel when it reaches the
RWM in the middle ear at body temperature. Among these sol–
gel polymers, poloxamer solution is liquid at room temperature
and forms a gel after intratympanic injection, increasing the
residence time of the drug in the middle ear. Salt et al.88 evaluated
the potential of a poloxamer hydrogel formulation containing
dexamethasone in intratympanic delivery to the RWM of guinea
pigs and analyzed the effects of the duration of drug application
on drug concentration in the cochlea of guinea pigs and humans.
Besides enhancing drug delivery to the inner ear, the increase in
residence time of the drug on the RWM could also lead to more
uniform drug distribution in the cochlea. Particularly, the drug
concentration gradient along the length of the cochlea was shown
to be signiﬁcantly affected by the duration of drug application
(i.e., residence time on RWM): higher drug concentration and
smaller drug concentration gradient in the cochlea were observed
with prolonged drug delivery on the RWM (Fig. 2). In addition to
the study by Salt et al.88, Wang et al.89 also utilized poloxamer
combined with micronized dexamethasone in inner ear delivery to
prolong drug residence in the ear. Paulson et al.90 developed a
Table 3 Brief review of recent developments in intratympanic drug delivery.
Drug delivery system Drug Signiﬁcant ﬁnding Ref.
Gelfoams Gentamicin Provided more consistent outcomes with
transtympanic delivery of gentamicin, controlled
vertigo in 75% of cases and improved tinnitus in
48% of the cases
78
Gelfoams Brain-derived
neurotrophic factor
(BDNF)
Local BDNF treatment enhanced the survival of cells
in basal turn of the cochlea
79
Gelfoams Neurotrophins-3 No protective effect on the cells in the cochlea of
guinea pigs
24
Hyaluronic gel Neomycin Had no toxic effect on the hair cells but temporary
increased the thickness of RWM
80
SeprapackTM Dexamethasone Provided protection of hearing across the entire
frequency domain (2–32 kHz)
81
SeprapackTM N-acetyl cysteine Increased the level of residual hearing at 24–32 kHz 4
weeks post-surgery compared to the controls
82
SeprapackTM Dexamethasone Provided higher and sustained drug concentrations in
the cochlear ﬂuid
83
Thiol-modiﬁed Hyaluronic
acid
Dexamethasone Provided higher and sustained perilymph drug
concentration
84
Glutaradehyde cross linking
of porcine type-collagen
Brain-derived
neurotrophic factor
Spiral ganglion neuron (SGN) densities were greater
than controls in the basal turn of the cochlea 3
months after implantation
85
Gelatin Growth factor Reduced the noise exposure-induced ABR threshold
shifts and the loss of outer hair cells in the basal
portion of cochlea
86
Chitosan glycosylated
derivative
Neomycin A safe and effective carrier for inner ear therapy
although causes the round window membrane
(RWM) to swell
87
Poloxamer 407 Dexamethasone Provided more uniform distribution of drug in the
inner ear
88
Poloxamer 407 Dexamethasone Sustained drug levels in the inner ear for a period of
at least 1–2 weeks
89
Chitosan glycerophosphate
hydrogel
Dexamethasone Provided measurable dexamethasone in perilymph for
5 days, and auditory testing revealed a temporary
hearing loss, which resolved by the 10th post-
operative day
90
Nanoparticles
Lipid core nanocapsules
poly L-lysine (HBPL)
nanoparticles
Distributed throughout the human inner ear cell
populations through the RWM of human temporal
bone
91
Superparamagnetic iron
oxide nanoparticles
Dextran Distributed through a 3-cell layer RWM model under
an external magnetic ﬁeld
92
Superparamagnetic iron
oxide nanoparticles
encapsulated Pluronic
F127 copolymer
Nanoparticles were seen throughout the inner ear
cells
93
Polymersome Provided speciﬁc targeting and binding afﬁnity to
SGNs, Schwann cells, and nerve ﬁbers
94
Superparamagnetic iron
oxide nanoparticles
encapsulated PLGA
nanoparticles
Provided nanoparticle delivery in RWM models
(in vitro cell culture, in vivo rat and guinea pig, and
in vitro human temporal bone) under a magnetic
ﬁeld
95
PLGA nanoparticles Rhodamine Higher distribution of rhodamine in the cochlea 48
Silica nanoparticles Cy3-labeled nanoparticles were found in the sensory
hair cells and the SGNs
96
Lipid nanocapsules Provided delivery to SGNs, organ of Corti and lateral
wall with no hearing impairment, cell death, or
morphological changes in the inner ear
97,98
Gelfoams: gelatin sponge; SeprapackTM: hyaluronic acid–carboxymethlcellulose polymer.
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Hongzhuo Liu et al.92drug delivery system based on a chitosan glycerophosphate
hydrogel, a biodegradable matrix that is temperature-sensitive to
achieve sustained delivery of dexamethasone from the RWM over
5 days. The chitosan glycerophosphate hydrogel system was found
to be safe, with no identiﬁed toxicities or complications from the
procedure in a murine model. Ten days after the treatment,
hearing thresholds returned to pretreatment baseline levels after an
initial transient elevation of the threshold. This temporary hearing
loss was suggests to be a result of conductive hearing loss related
to the presence of the hydrogel in the middle ear and/or ﬂuid
associated with immediate post-operative changes.4.2.2. Nanoparticles
In addition to hydrogel systems, nanoparticles have been studied
for drug delivery through the RWM to the inner ear. Because
nanoparticles can offer targeted drug delivery to speciﬁc cells in
the cochlea, they provide certain advantages over conventional
drug delivery methods. Roy et al.91 compared the ability of three
types of nanoparticles to permeate the RWM on fresh frozen
human temporal bone: polymersome nanoparticles of amphi-
philic poly (ethylene glycol)-b-poly (e-caprolactone) (PEG-b-
PCL) block copolymers, lipid core nanocapsules (LNCs) of
lecithin and stearate of PEG, and nanoparticles of hyper-
branched poly L-lysine (HBPL). It was found that these
nanoparticles can pass through the RWM in vitro. Mondalek
et al.92 tested a delivery system of superparamagnetic iron oxide
nanoparticles (SPIONs) through a 3-cell layer RWM model
in vitro. The results showed that SPIONs distributed throughout
the model membrane under an external magnetic ﬁeld. In
another study, Thaler et al.93 investigated the capability of
ferrogel consisting of SPIONs and Pluronic F127 with an
imaging tag for the delivery of therapeutic agents across the
RWM of cadaver human temporal bones as well as in organo-
typic explant cultures of mouse inner ears. It was found that the
SPIONs were in the cytoplasm in organotypic explant culture,
suggesting that the nanoparticle system can be a suitable cell
speciﬁc drug delivery vehicle that prevents drug degradation in
the cell endolysosomal compartment during drug delivery. Roy
et al.94 examined the cell targeting ability and toxicity of nerve
growth factor-derived ligand functionalized polymersome nano-
particles for speciﬁc cell targeting to SGNs in mouse cochlearFigure 2 Effect of the duration of dexamethasone (Dex) application
concentration gradient of Dex along the length of the cochlea. The data
with the RWM, e.g., via sustained drug delivery systems, can provide
application, squares; 6 h application, triangles; 24 h application, diamorganotypic culture and observed speciﬁc targeting to SGNs,
Schwann cells and nerve ﬁbers in the cochlear culture. However,
due to the potential difference between RWM permeability
in vitro and in vivo, the presence of cochlear clearance in vivo,
and the differences between in vitro cell culture models and
human cells in vivo, it is unclear if the in vitro permeation and cell
culture results can be extrapolated to humans in vivo.
With the differences between in vitro and in vivo experiments,
in vivo studies of inner ear drug delivery are preferred. Among the
nanoparticle studies in vivo, superparamagnetic iron oxide encap-
sulated in PLGA nanoparticles were investigated and found to
distribute throughout all turns of the cochlea of chinchilla95.
Tamura et al.48 showed higher distribution of rhodamine to the
cochlea after application of rhodamine encapsulated PLGA
nanoparticles on RWM as compared to systemic application,
illustrating that PLGA nanoparticles can be a useful drug carrier
for inner ear delivery. Besides PLGA-based nanoparticles, Prae-
torius and co-workers reported that silica nanoparticles labeled
with ﬂuorescent cyanine dye could be delivered to inner hair cells,
vestibular hair cells, and the spiral ganglia by the application of
the nanoparticle solution to the RWM96. These nanoparticles were
observed not to alter hearing threshold, and no cytotoxicity was
found to be associated with the treatment. Zou et al.97 evaluated
the ability of LNCs for inner ear drug delivery and found that
these nanocapsules rapidly reached the spiral ganglion cells, nerve
ﬁbers, hair cells and spiral ligament ﬁbrocytes after placement on
the RWM. The biocompatibility of these nanocapsules in inner
ear drug delivery was also evaluated. It was shown that the
administration of nanocapsules did not cause hearing loss, cell
death or morphological changes in the inner ear for up to 28 days
after the application98. In summary, nanoparticles are a promising
approach for inner ear drug delivery via intratympanic adminis-
tration, especially for gene delivery because of their cellular uptake
properties.5. Biotechnology-based approaches of inner ear drug delivery
Biotechnology-based drug delivery has been used extensively
in various ﬁelds of drug delivery. For inner ear delivery,
biological therapies of inner ear disorders have been investi-
gated to provide long-term drug delivery with the advantagesto the round window of guinea pig (A) and human (B) upon the
suggest an increase in the contact time of the drug delivery system
a more uniform drug distribution in the cochlea. Symbols: 30 min
onds. Data were obtained from Salt et al.88.
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Biotechnology-based approaches to inner ear treatments
include gene and stem cell therapies.
5.1. Gene therapy
Studies on the cellular and molecular mechanisms governing
hair cell differentiation and regeneration in animal model
systems have identiﬁed genes that may be targets of genetic
manipulation in humans that can lead to protection, replace-
ment, and/or regeneration of functional hair cells, supporting
cells, spiral neurons and strial cells99. Until recently, systems
for gene transfer to the inner ear have mainly focused on the
utility of replication defective viral vectors, including adeno-
virus, adeno-associated virus (AAV), and herpes virus100. For
example, adenoviruses were shown to transfer functional
marker genes such as beta-galactosidase (b gal) and green
ﬂuorescent protein (GFP) as well as genes that alter the
biology of the inner ear, such as glial-derived neurotrophic
factor (GDNF), to the auditory system101,102. Besides viral
vectors, liposomes have been investigated as a non-viral
delivery system but were found to be less efﬁcient in gene
transfer than viral vectors100. Recently, Praetorius and co-
workers96 suggested that silica nanoparticles might be a
potential non-viral vector for the sensory hair cells and spiral
ganglion cells in the cochlea and the vestibular organ when the
nanoparticles were administered to the round window niche.
Other recent development includes the ﬁndings by Tan et al. of
polycationic-mediated cochlear gene transfer with linear poly-
ethylenimine via cochleostomy and osmotic pump infusion
method103 but the polyethylenimine has relatively low trans-
fection efﬁciency as compared with viral vectors.
The identiﬁcation of gene targeting for inner ear disorder
and the demonstration of effective gene transfer for gene
delivery have shown promise in gene therapy for inner ear
disorders. However, successful cochlear gene delivery relies
not only on the gene delivery systems but also on the delivery
routes58. Different routes of administration to the cochlea
have been investigated with various purposes, such as max-
imizing transduced efﬁcacy, reducing cochlear toxicity, and/or
preserving hearing function. Viral transgenes injected directly
into the ST can provide reporter gene expression in SGNs,
hair cells, and supporting cells in the organ of Corti104–106.
Injection of gene transfer vehicles directly into SM can result
in efﬁcient transduction of hair cells and supporting
cells107,108. On the other hand, the intratympanic route that
requires gene delivery across the RWM by diffusion can
preserve the cochlear integrity, but offer less efﬁcient trans-
duction in the inner ear cells62.
5.2. Stem cell therapy
Stem cell therapy to treat hearing loss has recently received
attention due to its potential to replace and/or protect hair
cells and SGNs after deafness. The feasibility of stem cell
therapy in the treatment of inner ear disorders to replace
damaged hair cells has been previously reported109. It was
suggested that the implantation of embryonic stem cells, fetal
dorsal root ganglion and otocyst cells in the inner ear could be
used to restore damaged hair cells110,111. These ﬁndings for cell
transplantation have shown an opportunity to repopulatedamaged sensory epithelia in humans that might be an
alternative to gene therapy to reverse profound deafness. In
spite of these successes, an effective delivery method for stem
cells to the inner ear is needed.6. Concluding observations and future trends
The prospect of efﬁcacious inner ear drug delivery in the
future lies within either the non-invasively administered
sustained release systems via the ntratympanic approach or
systems in which drugs are administered via targeted and
highly efﬁcacious intracochlear routes. This is because sys-
temic drug delivery can lead to systemic adverse effects.
Although the use of systemic nanoparticles (via systemic
delivery) to achieve greater drug distribution to the cochlea
has shown promise, adverse effects from the drugs or nano-
particles in systemic circulation and/or other organs remain a
main concern. While the intracochlear approach can deliver
drugs directly to the inner ear, it involves high risks such as
inner ear trauma and hearing loss. Intratympanic drug
delivery can bypass the BLB, resulting in higher drug levels
in the inner ear with less systemic drug exposure. This
approach is relatively safe compared to intracochlear drug
delivery. However, inner ear drug delivery via the intratym-
panic route relies on drug permeation through the RWM, the
barrier between the middle ear and inner ear. In addition,
intratympanic drug delivery to the inner ear can be signiﬁ-
cantly affect by the residence time of drugs in contact with
RWM, which in turn can impact the clinical outcome.
The main problem encountered in intratympanic drug
delivery is the variability in drug delivery and unpredictable
bioavailability via this route, partly due to the variable
residence time of drugs in the middle ear. To overcome this
problem, various sustained drug release systems have been
employed to increase the residence time of drugs in the middle
ear and prolong drug contact with the RWM. This includes
the use of polymers, hydrogels, and nanoparticles as the
sustained release systems. Another problem in intratympanic
drug delivery is related to the rapid clearance of drugs in the
cochlea, resulting in low drug concentration in the apical
section of the cochlea. Hence, it is more difﬁcult to treat
hearing loss of low frequencies via this route. Reports on inner
ear drug delivery systems have suggested that nanoparticles
loaded with drugs can be distributed broadly in the inner ear
and enhance the delivery of drugs to the hair cells as well as
spiral neutron ganglions. The results in these studies are
encouraging and suggest that this approach can be the future
of inner ear disorder treatment.
Gene delivery and stem cell transplantation are also
promising approaches that can be used to treat inner ear
diseases. While recent studies using virus vectors for gene
delivery have shown no signiﬁcant toxicity, this risk remains a
potential problem in clinical application because the inner ear
is delicate and is located near the brain. Thus, until a complete
understanding of the safety proﬁles of virus vectors, non-virus
vectors might be better suited in gene transfer in the ear for
clinical use. In addition, there is a lack of effective methods to
deliver these gene delivery systems and stem cells to the inner
ear, which needs to be addressed.
In order to develop an effective intratympanic drug delivery
system, an adequate evaluation method for inner ear drug
Hongzhuo Liu et al.94delivery is required. To date, researchers have employed both
in vitro and in vivo methods to investigate drug delivery
systems. For in vitro studies, generally, their purpose is to
characterize the physical properties of the drug delivery
systems before the in vivo animal studies. Consequently, the
ability of in vitro studies to predict in vivo results through, e.g.,
in vitro/in vivo correlation, is important. However, there are
few reports comparing the in vitro and in vivo methods.
Particularly, potential differences between the RWM
permeability in vitro and in vivo and the lack of cochlear
clearance in vitro can be signiﬁcant factors in the prediction of
perilymph pharmacokinetics. Future research and develop-
ment of an effective evaluation method for inner ear drug
delivery are needed. For in vivo studies, guinea pigs are
commonly used as an animal model since the morphology of
guinea pig inner ear is similar to that of human. However, the
interpretation of the pharmacokinetic data in guinea pigs
requires the consideration of the routes by which drugs
entered the cochlea and the distance from the basal turn to
the apical turn in guinea pigs compared to humans, which
could inﬂuence drug distribution in the cochlea. Accurate
measurements of drug levels in the inner ear ﬂuids can also be
complicated. Considering the small volume of cochlear ﬂuid in
guinea pigs (i.e., less than 10 mL), the determination of
drug concentration at different locations in the cochlea (e.g.,
different turns of the cochlea) can present a technical problem
and be a major source of errors in advancing our under-
standing of perilymph pharmacokinetics. Thus, caution must
be exercised in the analysis of the pharmacokinetic results in
the literature and the generalization of the results from in vitro
evaluation methods and in vivo animal models to humans.
Besides the lack of an established method in inner ear
drug pharmacokinetics research, the toxicity and safety of new
inner ear drug delivery systems are generally not well estab-
lished. The inner ear is a complicated and subtle organ.
Adverse effects and complications in inner ear drug delivery
can lead to severe side effects such as hearing loss. Potential
ototoxicity of novel drug delivery systems should be carefully
examined. To be truly clinically useful, the drug delivery
systems should be both effective and safe, short of any
major risks, during inner ear disease treatment. These are
the current major hurdles of effective drug delivery to the
inner ear.References
1. Swan EE, Mescher MJ, Sewell WF, Tao SL, Borenstein JT.
Inner ear drug delivery for auditory applications. Adv Drug Deliv
Rev 2008;60:1583–99.
2. Borkholder DA. State-of-the-art mechanisms of intracochlear drug
delivery. Curr Opin Otolaryngol Head Neck Surg 2008;16:472–7.
3. Salt AN, Plontke SK. Principles of local drug delivery to the
inner ear. Audiol Neurootol 2009;14:350–60.
4. McCall AA, Swan EE, Borenstein JT, Sewell WF, Kujawa SG,
McKenna MJ. Drug delivery for treatment of inner ear disease:
current state of knowledge. Ear Hear 2010;31:156–65.
5. Staecker H, Jolly C, Garnham C. Cochlear implantation: an
opportunity for drug development. Drug Discov Today
2010;15:314–21.
6. Chen G, Zhang X, Yang F, Mu L. Disposition of nanoparticle-
based delivery system via inner ear administration. Curr Drug
Metab 2010;11:886–97.7. Borenstein JT. Intracochlear drug delivery systems. Expert Opin
Drug Deliv 2011;8:1161–74.
8. Nakagawa T, Ito J. Local drug delivery to the inner ear using
biodegradable materials. Ther Deliv 2011;2:807–14.
9. Mukherjea D, Rybak LP, Sheehan KE, Kaur T, Ramkumar V,
Jajoo S, et al. The design and screening of drugs to prevent
acquired sensorineural hearing loss. Expert Opin Drug Discov
2011;6:491–505.
10. Pyykko I, Zou J, Zhang W, Zhang Y. Nanoparticle-based
delivery for the treatment of inner ear disorders. Curr Opin
Otolaryngol Head Neck Surg 2011;19:388–96.
11. Rivera T, Sanz L, Camarero G, Varela-Nieto I. Drug delivery to
the inner ear: strategies and their therapeutic implications for
sensorineural hearing loss. Curr Drug Deliv 2012;9:231–42.
12. Pararas EE, Borkholder DA, Borenstein JT. Microsystems
technologies for drug delivery to the inner ear. Adv Drug Deliv
Rev 2012;64:1650–60.
13. Jahnke K. Permeability barriers of the inner ear. Fine structure
and function. Fortschr Med 1980;98:330–6.
14. Jahnke K. The blood–perilymph barrier. Arch Otorhinolaryngol
1980;228:29–34.
15. Juhn SK. Barrier systems in the inner ear. Acta Otolaryngol
Suppl 1988;458:79–83.
16. Juhn SK, Rybak LP. Labyrinthine barriers and cochlear home-
ostasis. Acta Otolaryngol 1981;91:529–34.
17. Saito T, Zhang ZJ, Tokuriki M, Ohtsubo T, Noda I, Shibamori
Y, et al. Expression of p-glycoprotein is associated with that of
multidrug resistance protein 1 (MRP1) in the vestibular labyr-
inth and endolymphatic sac of the guinea pig. Neurosci Lett
2001;303:189–92.
18. Yamasoba T, Suzuki M, Kaga K. Inﬂuence of chronic kana-
mycin administration on basement membrane anionic sites in the
labyrinth. Hear Res 1996;102:116–24.
19. Suzuki M, Yamasoba T, Ishibashi T, Miller JM, Kaga K. Effect
of noise exposure on blood-labyrinth barrier in guinea pigs.
Hear Res 2002;164:12–8.
20. Kastenbauer S, Klein M, Koedel U, Pﬁster HW. Reactive
nitrogen species contribute to blood–labyrinth barrier disruption
in suppurative labyrinthitis complicating experimental pneumo-
coccal meningitis in the rat. Brain Res 2001;904:208–17.
21. McFadden SL, Ding D, Jiang H, Woo JM, Salvi RJ. Chinchilla
models of selective cochlear hair cell loss. Hear Res
2002;174:230–8.
22. Tran Ba Huy P, Manuel C, Meulemans A, Sterkers O, Wassef M,
Amiel C. Ethacrynic acid facilitates gentamicin entry into endo-
lymph of the rat. Hear Res 1983;11:191–202.
23. Juhn SK, Prado S, Pearce J. Osmolality changes in perilymph
after systemic administration of glycerin. Arch Otolaryngol
1976;102:683–5.
24. Richardson RT, Noushi F, O’Leary S. Inner ear therapy for
neural preservation. Audiol Neurootol 2006;11:343–56.
25. Banerjee A, Parnes LS. The biology of intratympanic drug
administration and pharmacodynamics of round window drug
absorption. Otolaryngol Clin North Am 2004;37:1035–51.
26. Goycoolea MV, Lundman L. Round window membrane. Struc-
ture function and permeability: a review. Microsc Res Tech
1997;36:201–11.
27. Salt AN, Plontke SK. Local inner-ear drug delivery and
pharmacokinetics. Drug Discov Today 2005;10:1299–306.
28. Kim CS, Cho TK, Jinn TH. Permeability of the round window
membrane to horseradish peroxidase in experimental otitis
media. Otolaryngol Head Neck Surg 1990;103:918–25.
29. Hamaguchi Y, Morizono T, Juhn SK. Round window mem-
brane permeability to human serum albumin in antigen-induced
otitis media. Am J Otolaryngol 1988;9:34–40.
30. Hoft J. The permeability of the round window membrane and its
changes by pantocaine (tetracaine). Arch Klin Exp Ohren Nasen
Kehlkopfheilkd 1969;193:128–37.
Current strategies for drug delivery to the inner ear 9531. Ikeda K, Morizono T. Changes of the permeability of round
window membrane in otitis media. Arch Otolaryngol Head Neck
Surg 1988;114:895–7.
32. Chandrasekhar SS, Rubinstein RY, Kwartler JA, Gatz M,
Connelly PE, Huang E, et al. Dexamethasone pharmacokinetics
in the inner ear: comparison of route of administration and use
of facilitating agents. Otolaryngol Head Neck Surg
2000;122:521–8.
33. Mikulec AA, Hartsock JJ, Salt AN. Permeability of the round
window membrane is inﬂuenced by the composition of applied
drug solutions and by common surgical procedures. Otol
Neurotol 2008;29:1020–6.
34. Bowe SN, Jacob A. Round window perfusion dynamics: impli-
cations for intracochlear therapy. Curr Opin Otolaryngol Head
Neck Surg 2010;18:377–85.
35. Lasak JM, Sataloff RT, Hawkshaw M, Carey TE, Lyons KM,
Spiegel JR. Autoimmune inner ear disease: steroid and cytotoxic
drug therapy. Ear Nose Throat J 2001;80:808–11. 815–6,818
passim.
36. Wei BP, Mubiru S, O’Leary S. Steroids for idiopathic sudden
sensorineural hearing loss. Cochrane Database Syst Rev
2006;25:CD003998.
37. Sakamoto T, Nakagawa T, Horie RT, Hiraumi H, Yamamoto
N, Kikkawa YS, et al. Inner ear drug delivery system from the
clinical point of view. Acta Otolaryngol Suppl 2010;563:101–4.
38. Murai K, Tyler RS, Harker LA, Stouffer JL. Review of
pharmacologic treatment of tinnitus. Am J Otol 1992;13:454–64.
39. Berryhill WE, GrahamMD. Chemical and physical labyrinthect-
omy for Meniere’s disease. Otolaryngol Clin North Am 2002;35:
675–82.
40. Sataloff RT, McCarter A, Spiegel JR. Very high-dose strepto-
mycin labyrinthectomy. Ear Nose Throat J 1996;75:239–43.
41. Sajjadi H, Paparella MM. Meniere’s disease. Lancet
2008;372:406–14.
42. Lautermann J, McLaren J, Schacht J. Glutathione protection
against gentamicin ototoxicity depends on nutritional status.
Hear Res 1995;86:15–24.
43. Sha SH, Schacht J. Salicylate attenuates gentamicin-induced
ototoxicity. Lab Invest 1999;79:807–13.
44. Fetoni AR, Sergi B, Ferraresi A, Paludetti G, Troiani D. alpha-
Tocopherol protective effects on gentamicin ototoxicity: an
experimental study. Int J Audiol 2004;43:166–71.
45. Fetoni AR, Sergi B, Scarano E, Paludetti G, Ferraresi A,
Troiani D. Protective effects of alpha-tocopherol against
gentamicin-induced Oto-vestibulo toxicity: an experimental
study. Acta Otolaryngol 2003;123:192–7.
46. Unal OF, Ghoreishi SM, Atas A, Akyurek N, Akyol G, Gursel B.
Prevention of gentamicin induced ototoxicity by trimetazidine in
animal model. Int J Pediatr Otorhinolaryngol 2005;69:193–9.
47. Long M, Smouha EE, Qiu D, Li F, Johnson F, Luft B.
Flavanoid of Drynaria fortunei protects against gentamicin
ototoxicity. Phytother Res 2004;18:609–14.
48. Tamura T, Kita T, Nakagawa T, Endo T, Kim TS, Ishihara T,
et al. Drug delivery to the cochlea using PLGA nanoparticles.
Laryngoscope 2005;115:2000–5.
49. Horie RT, Sakamoto T, Nakagawa T, Ishihara T, Higaki M, Ito
J. Stealth-nanoparticle strategy for enhancing the efﬁcacy of
steroids in mice with noise-induced hearing loss. Nanomedicine
(Lond) 2010;5:1331–40.
50. Ersner MS, Spiegel EA, Alexander MH. Transtympanic injec-
tion of anesthetics for the treatment of Meniere’s syndrome.
AMA Arch Otolaryngol 1951;54:43–52.
51. Lange G. Gentamicin and other ototoxic antibiotics for the
transtympanic treatment of Meniere’s disease. Arch Otorhinolar-
yngol 1989;246:269–70.
52. Blakley BW. Clinical forum: are view of in tratympanic therapy.
Am J Otol 1997;18:520-6; discussion 527–31.53. Barrs DM. Intratympanic corticosteroids for Meniere’s disease
and vertigo. Otolaryngol Clin North Am 2004;37:955–72. [v].
54. Dodson KM, Woodson E, Sismanis A. Intratympanic steroid
perfusion for the treatment of Meniere’s disease: a retrospective
study. Ear Nose Throat J 2004;83:394–8.
55. Barrs DM, Keyser JS, Stallworth C, McElveen Jr. JT. Intra-
tympanic steroid injections for intractable Meniere’s disease.
Laryngoscope 2001;111:2100–4.
56. Banerjee A, Parnes LS. Intratympanic corticosteroids for sudden
idiopathic sensorineural hearing loss. Otol Neurotol 2005;26:878–81.
57. Rauch SD. Intratympanic steroids for sensorineural hearing loss.
Otolaryngol Clin N Am 2004;37:1061–74.
58. Richardson RT, Wise AK, Andrew JK, O’Leary SJ. Novel drug
delivery systems for inner ear protection and regeneration after
hearing loss. Expert Opin Drug Deliv 2008;5:1059–76.
59. Plontke SK, Mynatt R, Gill RM, Borgmann S, Salt AN.
Concentration gradient along the scala tympani after local
application of gentamicin to the round window membrane.
Laryngoscope 2007;117:1191–8.
60. Plontke SK, Wood AW, Salt AN. Analysis of gentamicin
kinetics in ﬂuids of the inner ear with round window adminis-
tration. Otol Neurotol 2002;23:967–74.
61. Salt AN, Ma Y. Quantiﬁcation of solute entry into cochlear
perilymph through the round window membrane. Hear Res
2001;154:88–97.
62. Stover T, Yagi M, Raphael Y. Cochlear gene transfer: round
window versus cochleostomy inoculation. Hear Res
1999;136:124–30.
63. Rejali D, Lee VA, Abrashkin KA, Humayun N, Swiderski DL,
Raphael Y. Cochlear implants and ex vivo BDNF gene therapy
protect spiral ganglion neurons. Hear Res 2007;228:180–7.
64. Richardson RT, Thompson B, Moulton S, Newbold C, Lum MG,
Cameron A, et al. The effect of polypyrrole with incorporated
neurotrophin-3 on the promotion of neurite outgrowth from
auditory neurons. Biomaterials 2007;28:513–23.
65. Pararas EE, Chen Z, Fiering J, Mescher MJ, Kim ES, McKenna
MJ, et al. Kinetics of reciprocating drug delivery to the inner ear.
J Control Release 2011;152:270–7.
66. Sewell WF, Borenstein JT, Chen Z, Fiering J, Handzel O,
Holmboe M, et al. Development of a microﬂuidics-based
intracochlear drug delivery device. Audiol Neurootol
2009;14:411–22.
67. Adunka O, Unkelbach MH, Mack M, Hambek M, Gstoettner W,
Kiefer J. Cochlear implantation via the round window membrane
minimizes trauma to cochlear structures: a histologically controlled
insertion study. Acta Otolaryngol 2004;124:807–12.
68. Nadol Jr. JB, Shiao JY, Burgess BJ, Ketten DR, Eddington DK,
Gantz BJ, et al. Histopathology of cochlear implants in humans.
Ann Otol Rhinol Laryngol 2001;110:883–91.
69. Hochman J, Blakley B, Abdoh A, Aleid H. Post-tympanostomy
tube otorrhea: a meta-analysis. Otolaryngol Head Neck Surg
2006;135:8–11.
70. Licameli G, Johnston P, Luz J, Daley J, Kenna M.
Phosphorylcholine-coated antibiotic tympanostomy tubes: are
post-tube placement complications reduced?. Int J Pediatr
Otorhinolaryngol 2008;72:1323–8.
71. Light JP, Silverstein H. Transtympanic perfusion: indicati
ons and limitations. Curr Opin Otolaryngol Head Neck
Surg 2004;12:378–83.
72. Silverstein H. Use of a new device, the MicroWick, to deliver
medication to the inner ear. Ear Nose Throat J 1999;78:595–8.
600.
73. Hill 3rd SL, Digges EN, Silverstein H. Long-term follow-up
after gentamicin application via the Silverstein MicroWick in the
treatment of Meniere’s disease. Ear Nose Throat J 2006;85:494.
96, 98.
74. DeCicco MJ, Hoffer ME, Kopke RD, Wester D, Allen KA,
Gottshall K, et al. Round-window microcatheter-administered
Hongzhuo Liu et al.96microdose gentamicin: results from treatment of tinnitus asso-
ciated with Meniere’s disease. Int Tinnitus J 1998;4:141–3.
75. Plontke S, Lowenheim H, Preyer S, Leins P, Dietz K, Koitschev A,
et al. Outcomes research analysis of continuous intratympanic
glucocorticoid delivery in patients with acute severe to profound
hearing loss: basis for planning randomized controlled trials. Acta
Otolaryngol 2005;125:830–9.
76. Lefebvre PP, Staecker H. Steroid perfusion of the inner ear for
sudden sensorineural hearing loss after failure of conventional
therapy: a pilot study. Acta Otolaryngol 2002;122:698–702.
77. Marks S, Arenberg IK, Hoffer ME. Round window microcath-
eter administered microdose of gentamycin: an alternative in the
treatment of tinnitus in patients with Meniere’s disease. Lar-
yngorhinootologie 2000;79:327–31.
78. Silverstein H, Arruda J, Rosenberg SI, Deems D, Hester TO.
Direct round window membrane application of gentamicin in
the treatment of Meniere’s disease. Otolaryngol Head Neck Surg
1999;120:649–55.
79. Havenith S, Versnel H, Agterberg MJ, de Groot JC, Sedee RJ,
Grolman W, et al. Spiral ganglion cell survival after round
window membrane application of brain-derived neurotrophic
factor using gelfoam as carrier. Hear Res 2011;272:168–77.
80. Saber A, Laurell G, Bramer T, Edsman K, Engmer C, Ulfendahl
M. Middle ear application of a sodium hyaluronate gel loaded with
neomycin in a Guinea pig model. Ear Hear 2009;30:81–9.
81. Eastwood H, Chang A, Kel G, Sly D, Richardson R, O’Leary SJ.
Round window delivery of dexamethasone ameliorates local and
remote hearing loss produced by cochlear implantation
into the second turn of the guinea pig cochlea. Hear Res
2010;265:25–9.
82. Eastwood H, Pinder D, James D, Chang A, Galloway S,
Richardson R, et al. Permanent and transient effects of locally
delivered n-acetyl cysteine in a guinea pig model of cochlear
implantation. Hear Res 2010;259:24–30.
83. James DP, Eastwood H, Richardson RT, O’Leary SJ. Effects of
round window dexamethasone on residual hearing in a Guinea
pig model of cochlear implantation. Audiol Neurootol
2008;13:86–96.
84. Borden RC, Saunders JE, Berryhill WE, Krempl GA, Thomp-
son DM, Queimado L. Hyaluronic acid hydrogel sustains the
delivery of dexamethasone across the round window membrane.
Audiol Neurootol 2011;16:1–11.
85. Endo T, Nakagawa T, Kita T, Iguchi F, Kim TS, Tamura T,
et al. Novel strategy for treatment of inner ears using a
biodegradable gel. Laryngoscope 2005;115:2016–20.
86. Inaoka T, Nakagawa T, Kikkawa YS, Tabata Y, Ono K,
Yoshida M, et al. Local application of hepatocyte growth factor
using gelatin hydrogels attenuates noise-induced hearing loss in
guinea pigs. Acta Otolaryngol 2009;129:453–7.
87. Saber A, Strand SP, Ulfendahl M. Use of the biodegradable
polymer chitosan as a vehicle for applying drugs to the inner ear.
Eur J Pharm Sci 2010;39:110–5.
88. Salt AN, Hartsock J, Plontke S, LeBel C, Piu F. Distribution of
dexamethasone and preservation of inner ear function following
intratympanic delivery of a gel-based formulation. Audiol Neu-
rootol 2011;16:323–35.
89. Wang X, Dellamary L, Fernandez R, Harrop A, Keithley EM,
Harris JP, et al. Dose-dependent sustained release of dexametha-
sone in inner ear cochlear ﬂuids using a novel local delivery
approach. Audiol Neurootol 2009;14:393–401.
90. Paulson DP, Abuzeid W, Jiang H, Oe T, O’Malley BW, Li D. A
novel controlled local drug delivery system for inner ear disease.
Laryngoscope 2008;118:706–11.
91. Roy S, Glueckert R, Johnston AH, Perrier T, Bitsche M, Newman
TA, et al. Strategies for drug delivery to the human inner ear by
multifunctional nanoparticles. Nanomedicine (Lond) 2012;7:55–63.92. Mondalek FG, Zhang YY, Kropp B, Kopke RD, Ge X, Jackson
RL, et al. The permeability of SPION over an artiﬁcial three-
layer membrane is enhanced by external magnetic ﬁeld.
J Nanobiotechnol 2006;4:4.
93. Thaler M, Roy S, Fornara A, Bitsche M, Qin J, Muhammed M,
et al. Visualization and analysis of superparamagnetic iron oxide
nanoparticles in the inner ear by light microscopy and energy
ﬁltered TEM. Nanomedicine 2011;7:360–9.
94. Roy S, Johnston AH, Newman TA, Glueckert R, Dudas J,
Bitsche M, et al. Cell-speciﬁc targeting in the mouse inner ear
using nanoparticles conjugated with a neurotrophin-derived
peptide ligand: potential tool for drug delivery. Int J Pharm
2010;390:214–24.
95. Ge X, Jackson RL, Liu J, Harper EA, Hoffer ME, Wassel RA,
et al. Distribution of PLGA nanoparticles in chinchilla cochleae.
Otolaryngol Head Neck Surg 2007;137:619–23.
96. Praetorius M, Brunner C, Lehnert B, Klingmann C, Schmidt
H, Staecker H, et al. Transsynaptic delivery of nanoparticles to
the central auditory nervous system. Acta Otolaryngol
2007;127:486–90.
97. Zou J, Saulnier P, Perrier T, Zhang Y, Manninen T, Toppila E,
et al. Distribution of lipid nanocapsules in different cochlear cell
populations after round window membrane permeation.
J Biomed Mater Res B Appl Biomater 2008;87:10–8.
98. Zhang Y, Zhang W, Lobler M, Schmitz KP, Saulnier P, Perrier T,
et al. Inner ear biocompatibility of lipid nanocapsules after round
window membrane application. Int J Pharm 2011;404:211–9.
99. Tang LS, Montemayor C, Pereira FA. Sensorineural hearing
loss: potential therapies and gene targets for drug development.
IUBMB Life 2006;58:525–30.
100. Staecker H, Brough DE, Praetorius M, Baker K. Drug delivery
to the inner ear using gene therapy. Otolaryngol Clin North Am
2004;37:1091–108.
101. Raphael Y, Frisancho JC, Roessler BJ. Adenoviral-mediated
gene transfer into guinea pig cochlear cells in vivo. Neurosci Lett
1996;207:137–41.
102. Yagi M, Magal E, Sheng Z, Ang KA, Raphael Y. Hair cell
protection from aminoglycoside ototoxicity by adenovirus-
mediated overexpression of glial cell line-derived neurotrophic
factor. Hum Gene Ther 1999;10:813–23.
103. Tan BT, Foong KH, Lee MM, Ruan R. Polyethylenimine-
mediated cochlear gene transfer in guinea pigs. Arch Otolaryngol
Head Neck Surg 2008;134:884–91.
104. Li Duan M, Bordet T, Mezzina M, Kahn A, Ulfendahl M.
Adenoviral and adeno-associated viral vector mediated gene
transfer in the guinea pig cochlea. Neuroreport 2002;13:1295–9.
105. Praetorius M, Knipper M, Schick B, Tan J, Limberger A,
Carnicero E, et al. A novel vestibular approach for gene transfer
into the inner ear. Audiol Neurootol 2002;7:324–34.
106. Luebke AE, Steiger JD, Hodges BL, Amalﬁtano A. A modiﬁed
adenovirus can transfect cochlear hair cells in vivo without
compromising cochlear function. Gene Ther 2001;8:789–94.
107. Ishimoto S, Kawamoto K, Kanzaki S, Raphael Y. Gene transfer
into supporting cells of the organ of Corti. Hear Res
2002;173:187–97.
108. Wenzel GI, Xia A, Funk E, Evans MB, Palmer DJ, Ng P, et al.
Helper-dependent adenovirus-mediated gene transfer into the
adult mouse cochlea. Otol Neurotol 2007;28:1100–8.
109. Kojima K, Murata M, Nishio T, Kawaguchi S, Ito J. Survival of
fetal rat otocyst cells grafted into the damaged inner ear. Acta
Otolaryngol Suppl 2004;551:53–5.
110. Tateya I, Nakagawa T, Iguchi F, Kim TS, Endo T, Yamada S,
et al. Fate of neural stem cells grafted into injured inner ears of
mice. Neuroreport 2003;14:1677–81.
111. Hu Z, Wei D, Johansson CB, Holmstrom N, Duan M, Frisen J,
et al. Survival and neural differentiation of adult neural stem cells
transplanted into the mature inner ear. Exp Cell Res 2005;302:40–7.
